Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients

Alpár Horváth, I. Balásházy, Gábor Tomisa, Árpád Farkas

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aerosol drugs are effectively used to treat chronic respiratory diseases. The efficiency of the therapy depends also on the amount and distribution of drug deposited within the airways. The objective of this study is to apply numerical techniques to analyse the effect of the duration of breath-hold after the inhalation of six different commercialized dry powder drugs on their lung deposition. For this purpose a computational airway deposition model has been adapted and validated to the special case of therapeutic aerosols. Our results show that lung dose of the studied drugs can be enhanced by 11.3%–26.5% with a 5s breath-hold and by 20.7%–53% with a 25s breath-hold compared to the no-breath-hold case. Although this later duration may not be achieved by COPD patients, present results clearly show the importance of holding the breath as long as possible. Current computations also revealed that there is a strong positive correlation between the enhancement of lung dose as a result of breath-hold and the amount of fine particles in the drugs. Present tendencies aiming at producing drug particles of smaller and smaller sizes will lead to the further enhancement of the importance of producing a sufficiently long breath-hold time after the drug inhalation. In addition, higher lung deposition will be possible by the more correct use of inhalation devices, more precise and detailed patient information materials and personalized drug choice and therapy.

Original languageEnglish
Pages (from-to)145-149
Number of pages5
JournalEuropean Journal of Pharmaceutical Sciences
Volume104
DOIs
Publication statusPublished - Jun 15 2017

Fingerprint

Inhalation Administration
Powders
Chronic Obstructive Pulmonary Disease
Pharmaceutical Preparations
Lung
Aerosols
Breath Holding
Nebulizers and Vaporizers
Inhalation
Chronic Disease
Drug Therapy
Therapeutics

Keywords

  • Aerosol drug deposition
  • Breath-hold time
  • Drug delivery simulation
  • Dry powder inhaler

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients. / Horváth, Alpár; Balásházy, I.; Tomisa, Gábor; Farkas, Árpád.

In: European Journal of Pharmaceutical Sciences, Vol. 104, 15.06.2017, p. 145-149.

Research output: Contribution to journalArticle

@article{c6fbe9dcd3ea46dda471a9d70a8b59e4,
title = "Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients",
abstract = "Aerosol drugs are effectively used to treat chronic respiratory diseases. The efficiency of the therapy depends also on the amount and distribution of drug deposited within the airways. The objective of this study is to apply numerical techniques to analyse the effect of the duration of breath-hold after the inhalation of six different commercialized dry powder drugs on their lung deposition. For this purpose a computational airway deposition model has been adapted and validated to the special case of therapeutic aerosols. Our results show that lung dose of the studied drugs can be enhanced by 11.3{\%}–26.5{\%} with a 5s breath-hold and by 20.7{\%}–53{\%} with a 25s breath-hold compared to the no-breath-hold case. Although this later duration may not be achieved by COPD patients, present results clearly show the importance of holding the breath as long as possible. Current computations also revealed that there is a strong positive correlation between the enhancement of lung dose as a result of breath-hold and the amount of fine particles in the drugs. Present tendencies aiming at producing drug particles of smaller and smaller sizes will lead to the further enhancement of the importance of producing a sufficiently long breath-hold time after the drug inhalation. In addition, higher lung deposition will be possible by the more correct use of inhalation devices, more precise and detailed patient information materials and personalized drug choice and therapy.",
keywords = "Aerosol drug deposition, Breath-hold time, Drug delivery simulation, Dry powder inhaler",
author = "Alp{\'a}r Horv{\'a}th and I. Bal{\'a}sh{\'a}zy and G{\'a}bor Tomisa and {\'A}rp{\'a}d Farkas",
year = "2017",
month = "6",
day = "15",
doi = "10.1016/j.ejps.2017.03.047",
language = "English",
volume = "104",
pages = "145--149",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients

AU - Horváth, Alpár

AU - Balásházy, I.

AU - Tomisa, Gábor

AU - Farkas, Árpád

PY - 2017/6/15

Y1 - 2017/6/15

N2 - Aerosol drugs are effectively used to treat chronic respiratory diseases. The efficiency of the therapy depends also on the amount and distribution of drug deposited within the airways. The objective of this study is to apply numerical techniques to analyse the effect of the duration of breath-hold after the inhalation of six different commercialized dry powder drugs on their lung deposition. For this purpose a computational airway deposition model has been adapted and validated to the special case of therapeutic aerosols. Our results show that lung dose of the studied drugs can be enhanced by 11.3%–26.5% with a 5s breath-hold and by 20.7%–53% with a 25s breath-hold compared to the no-breath-hold case. Although this later duration may not be achieved by COPD patients, present results clearly show the importance of holding the breath as long as possible. Current computations also revealed that there is a strong positive correlation between the enhancement of lung dose as a result of breath-hold and the amount of fine particles in the drugs. Present tendencies aiming at producing drug particles of smaller and smaller sizes will lead to the further enhancement of the importance of producing a sufficiently long breath-hold time after the drug inhalation. In addition, higher lung deposition will be possible by the more correct use of inhalation devices, more precise and detailed patient information materials and personalized drug choice and therapy.

AB - Aerosol drugs are effectively used to treat chronic respiratory diseases. The efficiency of the therapy depends also on the amount and distribution of drug deposited within the airways. The objective of this study is to apply numerical techniques to analyse the effect of the duration of breath-hold after the inhalation of six different commercialized dry powder drugs on their lung deposition. For this purpose a computational airway deposition model has been adapted and validated to the special case of therapeutic aerosols. Our results show that lung dose of the studied drugs can be enhanced by 11.3%–26.5% with a 5s breath-hold and by 20.7%–53% with a 25s breath-hold compared to the no-breath-hold case. Although this later duration may not be achieved by COPD patients, present results clearly show the importance of holding the breath as long as possible. Current computations also revealed that there is a strong positive correlation between the enhancement of lung dose as a result of breath-hold and the amount of fine particles in the drugs. Present tendencies aiming at producing drug particles of smaller and smaller sizes will lead to the further enhancement of the importance of producing a sufficiently long breath-hold time after the drug inhalation. In addition, higher lung deposition will be possible by the more correct use of inhalation devices, more precise and detailed patient information materials and personalized drug choice and therapy.

KW - Aerosol drug deposition

KW - Breath-hold time

KW - Drug delivery simulation

KW - Dry powder inhaler

UR - http://www.scopus.com/inward/record.url?scp=85017153598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017153598&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2017.03.047

DO - 10.1016/j.ejps.2017.03.047

M3 - Article

C2 - 28389274

AN - SCOPUS:85017153598

VL - 104

SP - 145

EP - 149

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -